The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Oncotelic Therapeutics's share price is $0.038. Oncotelic Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.03. Hence, Oncotelic Therapeutics's PB Ratio of today is 1.27.
The historical rank and industry rank for Oncotelic Therapeutics's PB Ratio or its related term are showing as below:
OTLC'
s PB Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.94 Max: 11.48
Current: 1.27
During the past 13 years, Oncotelic Therapeutics's highest PB Ratio was 11.48. The lowest was 0.05. And the median was 0.94.
OTLC's PB Ratio is ranked better than 74.89% of 1310
companies
in the Biotechnology industry
Industry Median: 2.38
vs OTLC: 1.27
During the past 12 months, Oncotelic Therapeutics's average Book Value Per Share Growth Rate was -40.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncotelic Therapeutics was 64.30% per year. The lowest was -62.50% per year. And the median was -23.20% per year.
Back to Basics: PB Ratio
Oncotelic Therapeutics PB Ratio Historical Data
The historical data trend for Oncotelic Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncotelic Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics PB Ratio Distribution
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's PB Ratio falls into.
Oncotelic Therapeutics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Oncotelic Therapeutics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oncotelic Therapeutics (OTCPK:OTLC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oncotelic Therapeutics PB Ratio Related Terms
Thank you for viewing the detailed overview of Oncotelic Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLC has been successfully added to your 